GlassScriptPhysician profile
Robert J Schramm
NPI 1972516979
$16,944.24
in general payments reported to CMS, 2019-2025
44 companies · $4,334 in 2025
The $4,334 reported for 2025 was more than what 82% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,375 · 2020: $812 · 2021: $1,204 · 2022: $1,367 · 2023: $2,983 · 2024: $3,870 · 2025: $4,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,027.13 |
| Consulting Fee | $159.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,486.00 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,634.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,382.41 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,179.57 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $919.98 | 2020-2025 | Hyqvia |
| Amgen INC. | $794.16 | 2023-2025 | Tezspire |
| Optinose US, INC. | $485.19 | 2019-2025 | |
| Csl Behring | $389.37 | 2019-2025 | Hizentra, Haegarda |
| Octapharma USA, INC. | $386.36 | 2019-2025 | Octagam Immune Globulin (Human), Cutaquig, Panzyga |
| Pharming Healthcare, INC. | $342.72 | 2019-2025 | Ruconest, Joenja |
| Philips North America LLC | $336.86 | 2019-2024 | (Ak6) Vest Therapy |
| Pfizer INC. | $335.81 | 2020-2024 | |
| Galderma Laboratories, L.P. | $322.80 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $320.75 | 2023-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $305.52 | 2019-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $295.18 | 2019-2025 | Xolair |
| Kaleo, INC. | $279.16 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $267.35 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Adma Biomanufacturing LLC | $237.01 | 2021-2025 | |
| Shire North American Group INC | $200.00 | 2019 | |
| Incyte Corporation | $165.25 | 2021-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.37 | 2020-2023 | Spiriva |
| Ars Pharmaceuticals Operations, INC. | $155.64 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $143.26 | 2025 | Dawnzera |
| X4 Pharmaceuticals, INC. | $135.00 | 2024 | Xolremdi |
| Blueprint Medicines Corporation | $131.19 | 2024 | Ayvakit |
| Genentech, INC. | $125.00 | 2024 | Xolair |
| Sanofi US Services INC. | $119.81 | 2025 | |
| Bio Products Laboratory USA, INC. | $101.44 | 2021-2023 | Gammaplex, Coagadex |
| Alk-Abello, INC | $97.29 | 2022-2025 | Alternaria Tenuis, Pre-Pen, Standardized Mite D. Farinae |
| Teva Pharmaceuticals USA, INC. | $96.47 | 2019-2021 | |
| Grifols Shared Services North America, INC. | $94.43 | 2024 | Xembify |
| Aimmune Therapeutics, INC. | $93.29 | 2020-2022 | |
| Alcon Vision LLC | $87.48 | 2022 | |
| Mylan Specialty L.P. | $70.07 | 2019-2021 | |
| Leo Pharma INC. | $54.64 | 2023-2025 | Adbry, Anzupgo |
| Invivyd INC | $49.70 | 2025 | Pemgarda |
| Arcutis Biotherapeutics, INC. | $31.71 | 2025 | Zoryve |
| Hikma Pharmaceuticals USA | $28.51 | 2023 | Ryaltris |
| Insmed, INC. | $26.34 | 2025 | Arikayce |
| Circassia INC. | $20.98 | 2019 | |
| Paratek Pharmaceuticals, INC. | $19.91 | 2025 | Xhance |
| Abbvie INC. | $18.69 | 2023 | Rinvoq |
| Kedrion Biopharma, INC. | $17.39 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schramm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.